BEXIMCO PHARMAGDR (Germany) Performance
| R2WA Stock | EUR 0.45 0.02 4.65% |
On a scale of 0 to 100, BEXIMCO PHARMAGDR holds a performance score of 20. The firm shows a Beta (market volatility) of 0.21, which signifies not very significant fluctuations relative to the market. As returns on the market increase, BEXIMCO PHARMAGDR's returns are expected to increase less than the market. However, during the bear market, the loss of holding BEXIMCO PHARMAGDR is expected to be smaller as well. Please check BEXIMCO PHARMAGDR's potential upside, semi variance, and the relationship between the value at risk and downside variance , to make a quick decision on whether BEXIMCO PHARMAGDR's price patterns will revert.
Risk-Adjusted Performance
20 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in BEXIMCO PHARMAGDR REGS are ranked lower than 20 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, BEXIMCO PHARMAGDR reported solid returns over the last few months and may actually be approaching a breakup point. ...more
BEXIMCO |
BEXIMCO PHARMAGDR Relative Risk vs. Return Landscape
If you would invest 28.00 in BEXIMCO PHARMAGDR REGS on October 15, 2024 and sell it today you would earn a total of 17.00 from holding BEXIMCO PHARMAGDR REGS or generate 60.71% return on investment over 90 days. BEXIMCO PHARMAGDR REGS is generating 0.8442% of daily returns assuming 3.2762% volatility of returns over the 90 days investment horizon. Simply put, 29% of all stocks have less volatile historical return distribution than BEXIMCO PHARMAGDR, and 84% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
BEXIMCO PHARMAGDR Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BEXIMCO PHARMAGDR's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BEXIMCO PHARMAGDR REGS, and traders can use it to determine the average amount a BEXIMCO PHARMAGDR's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2577
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | R2WA | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.28 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.84 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.26 actual daily | 20 80% of assets perform better |
Based on monthly moving average BEXIMCO PHARMAGDR is performing at about 20% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BEXIMCO PHARMAGDR by adding it to a well-diversified portfolio.
BEXIMCO PHARMAGDR Fundamentals Growth
BEXIMCO Stock prices reflect investors' perceptions of the future prospects and financial health of BEXIMCO PHARMAGDR, and BEXIMCO PHARMAGDR fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BEXIMCO Stock performance.
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.14 % | |||
| Shares Outstanding | 446.11 M | |||
| Debt To Equity | 27.50 % | |||
| Earnings Per Share | 0.10 X | |||
About BEXIMCO PHARMAGDR Performance
By analyzing BEXIMCO PHARMAGDR's fundamental ratios, stakeholders can gain valuable insights into BEXIMCO PHARMAGDR's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BEXIMCO PHARMAGDR has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BEXIMCO PHARMAGDR has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulation products and active pharmaceutical ingredients. Beximco Pharmaceuticals Limited was founded in 1976 and is headquartered in Dhaka, Bangladesh. Beximco Pharmaceuticals operates under Drug Manufacturers - Major classification in Germany and traded on Frankfurt Stock Exchange.Things to note about BEXIMCO PHARMAGDR REGS performance evaluation
Checking the ongoing alerts about BEXIMCO PHARMAGDR for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BEXIMCO PHARMAGDR REGS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BEXIMCO PHARMAGDR has some characteristics of a very speculative penny stock | |
| BEXIMCO PHARMAGDR appears to be risky and price may revert if volatility continues |
- Analyzing BEXIMCO PHARMAGDR's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BEXIMCO PHARMAGDR's stock is overvalued or undervalued compared to its peers.
- Examining BEXIMCO PHARMAGDR's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BEXIMCO PHARMAGDR's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BEXIMCO PHARMAGDR's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BEXIMCO PHARMAGDR's stock. These opinions can provide insight into BEXIMCO PHARMAGDR's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BEXIMCO Stock analysis
When running BEXIMCO PHARMAGDR's price analysis, check to measure BEXIMCO PHARMAGDR's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BEXIMCO PHARMAGDR is operating at the current time. Most of BEXIMCO PHARMAGDR's value examination focuses on studying past and present price action to predict the probability of BEXIMCO PHARMAGDR's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BEXIMCO PHARMAGDR's price. Additionally, you may evaluate how the addition of BEXIMCO PHARMAGDR to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |